Arpitha Parthasarathy
US Medical Innovations, USA
Title: Selective ablation of ocular cancer cells and cancer stem cells with cold atmospheric plasma
Biography
Biography: Arpitha Parthasarathy
Abstract
Cold atmospheric plasma (CAP) activates pro-apoptotic signaling pathways triggered through redox potential in cancer cells leading to and decreased cell survival (Drs. Keidar and Canady’s group). We hypothesize that CAP may have a dramatic effect on these apoptotic pathways in cancer and cancer stem cells (CSC) and thereby reducing the application of chemotherapeutics. The present study aims at identifying newer targets and pathways that are involved in the down regulation of retinoblastoma and other CSC’s, cancer cell lines Canady Hybrid Plasma scalpels to address some of these important questions in plasma medicine and cancer therapeutics. Quantitative Confocal Microscopy, Q-PCR, Immunoblots for Nf-Kb mediated and apoptotic pathways, analysis of stem cell signaling via Beta-catenin using TIRF microscopy are some of the methods used in the current study. On the basis of the background literature and our preliminary results we hypothesize that CAP has a selective mechanism to ablate the CSCs. The outcome of the current study will enable cancer researchers to develop newer strategies along with CAP in the treatment of cancer.
Speaker Presentations
Speaker PPTs Click Here